About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

NCT01102231·38 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Intergroupe Francophone de Cancerologie Thoracique

Age

18–70

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

non-squamous stage III non-small cell lung cancer
measurable disease (RECIST 1.1)
ECOG performance status 0-1
normal organ and marrow function

You may not be if

prior chest radiation therapy
history of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma in situ of the cervix) within the last five years.
Prior therapy with known specific inhibitors of the EGFR.
history of severe allergic reaction to prior therapy with monoclonal antibodies

The record

StatusCompleted

PhasePhase 2

Taking part106

StartedMar 2010

UpdatedFeb 16, 2021

Conditions

Stage III Non-small Cell Lung Cancer

Where38

Clinique de l'Europe
Amiens, France
Centre Hospitalier
Annemasse, France
CHU Besancon - Pneumologie
Besançon, France

Clareo Health | Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)